Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PAMELA D DESILVA

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1568414548
CMS profile
635560
Location
PALMDALE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$49.45

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $49.45 2

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Amgen Inc. $33.45 1
Covidien LP $16.00 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PAMELA D DESILVA

NPI 1568414548 · CMS profile ID 635560

Allopathic & Osteopathic Physicians / Internal Medicine

PALMDALE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1568414548?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PAMELA D DESILVA, NPI 1568414548, CMS profile ID 635560. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1568414548?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). PAMELA D DESILVA, NPI 1568414548, CMS profile ID 635560. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1568414548?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
PAMELA D DESILVA, NPI 1568414548, CMS profile ID 635560, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1568414548?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $49.45 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $33.4501/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662847225 CMS
Covidien LP $16.0001/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 636973885 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $49.45 2
PY2021 $44.71 1
PY2022 $375.62 4
PY2023 $21.61 1
PY2024 $99.92 3
PY2025 $272.12 6

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $259,037.83 42
PY2024 Principal investigator $705,457.79 14
PY2023 Principal investigator $796,070.92 325
PY2022 Principal investigator $757,707.48 25
PY2021 Principal investigator $76,471.40 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

325 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $125,114.20 12/31/2023 Non-covered Recipient Entity
Chemidox Clinical Trials
A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine na Adults No dispute reported 06/30/2026 1042572695
Principal investigator 1 Merck Sharp & Dohme LLC $187,295.50 12/18/2023 Non-covered Recipient Entity
Chemidox Clinical Trials
A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine na Adults No dispute reported 06/30/2026 1042572687
Principal investigator 1 Bavarian Nordic A/S $2,000.00 12/08/2023 Non-covered Recipient Entity
CHEMIDOX CLINICAL TRIALS INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988708679
Principal investigator 1 Bavarian Nordic A/S $1,500.00 12/08/2023 Non-covered Recipient Entity
CHEMIDOX CLINICAL TRIALS INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988708819
Principal investigator 1 Bavarian Nordic A/S $2,500.00 12/08/2023 Non-covered Recipient Entity
CHEMIDOX CLINICAL TRIALS INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988708831
Principal investigator 1 PFIZER INC. $600.00 10/27/2023 Non-covered Recipient Entity
Chemidox Clinical Trials Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045864045
Principal investigator 1 ModernaTX, Inc. $1,013.20 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798099
Principal investigator 1 ModernaTX, Inc. $20.25 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798109
Principal investigator 1 ModernaTX, Inc. $1,013.20 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798117
Principal investigator 1 ModernaTX, Inc. $20.25 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798125
Principal investigator 1 ModernaTX, Inc. $1,961.98 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798133
Principal investigator 1 ModernaTX, Inc. $2,274.70 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798141
Principal investigator 1 ModernaTX, Inc. $2,483.95 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798151
Principal investigator 1 ModernaTX, Inc. $2,483.95 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798161
Principal investigator 1 ModernaTX, Inc. $2,483.95 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798171
Principal investigator 1 ModernaTX, Inc. $2,483.95 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798179
Principal investigator 1 ModernaTX, Inc. $2,274.70 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798187
Principal investigator 1 ModernaTX, Inc. $2,274.70 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798195
Principal investigator 1 ModernaTX, Inc. $2,483.95 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798203
Principal investigator 1 ModernaTX, Inc. $2,483.95 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798211
Principal investigator 1 ModernaTX, Inc. $2,274.70 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798219
Principal investigator 1 ModernaTX, Inc. $2,483.95 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798227
Principal investigator 1 ModernaTX, Inc. $5,209.87 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798235
Principal investigator 1 ModernaTX, Inc. $2,483.95 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798243
Principal investigator 1 ModernaTX, Inc. $20.25 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798251
Principal investigator 1 ModernaTX, Inc. $911.95 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798259
Principal investigator 1 ModernaTX, Inc. $1,013.20 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798267
Principal investigator 1 ModernaTX, Inc. $1,013.20 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798275
Principal investigator 1 ModernaTX, Inc. $20.25 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798283
Principal investigator 1 ModernaTX, Inc. $1,013.20 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798291
Principal investigator 1 ModernaTX, Inc. $2,483.95 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798299
Principal investigator 1 ModernaTX, Inc. $20.25 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798309
Principal investigator 1 ModernaTX, Inc. $20.25 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798317
Principal investigator 1 ModernaTX, Inc. $20.25 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798325
Principal investigator 1 ModernaTX, Inc. $2,483.95 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798333
Principal investigator 1 ModernaTX, Inc. $2,483.95 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798341
Principal investigator 1 ModernaTX, Inc. $2,483.95 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798349
Principal investigator 1 ModernaTX, Inc. $2,483.95 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798355
Principal investigator 1 ModernaTX, Inc. $2,483.95 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798363
Principal investigator 1 ModernaTX, Inc. $2,483.95 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798371
Principal investigator 1 ModernaTX, Inc. $911.95 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798379
Principal investigator 1 ModernaTX, Inc. $20.25 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798387
Principal investigator 1 ModernaTX, Inc. $2,274.70 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798395
Principal investigator 1 ModernaTX, Inc. $20.25 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798403
Principal investigator 1 ModernaTX, Inc. $20.25 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798412
Principal investigator 1 ModernaTX, Inc. $2,483.95 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798421
Principal investigator 1 ModernaTX, Inc. $2,274.70 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798429
Principal investigator 1 ModernaTX, Inc. $20.25 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798437
Principal investigator 1 ModernaTX, Inc. $2,274.70 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798445
Principal investigator 1 ModernaTX, Inc. $2,274.70 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798453
Principal investigator 1 ModernaTX, Inc. $20.25 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798461
Principal investigator 1 ModernaTX, Inc. $2,274.70 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798469
Principal investigator 1 ModernaTX, Inc. $20.25 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798476
Principal investigator 1 ModernaTX, Inc. $2,274.70 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798483
Principal investigator 1 ModernaTX, Inc. $20.25 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798491
Principal investigator 1 ModernaTX, Inc. $3,242.00 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798500
Principal investigator 1 ModernaTX, Inc. $5,209.87 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798509
Principal investigator 1 ModernaTX, Inc. $20.25 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798519
Principal investigator 1 ModernaTX, Inc. $20.25 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798525
Principal investigator 1 ModernaTX, Inc. $2,483.95 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798533
Principal investigator 1 ModernaTX, Inc. $2,483.95 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798541
Principal investigator 1 ModernaTX, Inc. $2,483.95 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798549
Principal investigator 1 ModernaTX, Inc. $2,483.95 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798557
Principal investigator 1 ModernaTX, Inc. $20.25 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798565
Principal investigator 1 ModernaTX, Inc. $911.95 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798573
Principal investigator 1 ModernaTX, Inc. $2,483.95 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798581
Principal investigator 1 ModernaTX, Inc. $2,483.95 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798589
Principal investigator 1 ModernaTX, Inc. $20.25 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798597
Principal investigator 1 ModernaTX, Inc. $3,402.27 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798607
Principal investigator 1 ModernaTX, Inc. $2,483.95 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798615
Principal investigator 1 ModernaTX, Inc. $1,961.98 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798623
Principal investigator 1 ModernaTX, Inc. $20.25 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798631
Principal investigator 1 ModernaTX, Inc. $2,483.95 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798639
Principal investigator 1 ModernaTX, Inc. $2,483.95 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798647
Principal investigator 1 ModernaTX, Inc. $20.25 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041799073
Principal investigator 1 ModernaTX, Inc. $911.95 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041799081
Principal investigator 1 ModernaTX, Inc. $20.25 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041799089
Principal investigator 1 ModernaTX, Inc. $2,274.70 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041799097
Principal investigator 1 ModernaTX, Inc. $20.25 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041799105
Principal investigator 1 ModernaTX, Inc. $20.25 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041799113
Principal investigator 1 ModernaTX, Inc. $2,483.95 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041799123
Principal investigator 1 ModernaTX, Inc. $2,274.70 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041799133
Principal investigator 1 ModernaTX, Inc. $20.25 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041799139
Principal investigator 1 ModernaTX, Inc. $20.25 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041799147
Principal investigator 1 ModernaTX, Inc. $3,242.00 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041799155
Principal investigator 1 ModernaTX, Inc. $20.25 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041799165
Principal investigator 1 ModernaTX, Inc. $911.95 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041799173
Principal investigator 1 ModernaTX, Inc. $2,483.95 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041799181
Principal investigator 1 ModernaTX, Inc. $20.25 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041799189
Principal investigator 1 ModernaTX, Inc. $2,483.95 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041799197
Principal investigator 1 ModernaTX, Inc. $2,274.70 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041799205
Principal investigator 1 ModernaTX, Inc. $20.25 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041799213
Principal investigator 1 ModernaTX, Inc. $2,483.95 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041799221
Principal investigator 1 ModernaTX, Inc. $3,402.27 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041799229
Principal investigator 1 ModernaTX, Inc. $2,483.95 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041799237
Principal investigator 1 ModernaTX, Inc. $2,483.95 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041799245
Principal investigator 1 ModernaTX, Inc. $20.25 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041799253
Principal investigator 1 ModernaTX, Inc. $2,274.70 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041799261
Principal investigator 1 ModernaTX, Inc. $20.25 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041799269
Principal investigator 1 ModernaTX, Inc. $20.25 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041799277
Principal investigator 1 ModernaTX, Inc. $20.25 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041799285
Principal investigator 1 ModernaTX, Inc. $2,483.95 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041799293
Principal investigator 1 ModernaTX, Inc. $20.25 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041799301
Principal investigator 1 ModernaTX, Inc. $5,209.87 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041799309
Principal investigator 1 ModernaTX, Inc. $2,483.95 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041799317
Principal investigator 1 ModernaTX, Inc. $20.25 10/26/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041799323
Principal investigator 1 PFIZER INC. $8,840.00 10/24/2023 Non-covered Recipient Entity
Chemidox Clinical Trials Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045864057
Principal investigator 1 Bavarian Nordic A/S $1,113.00 10/10/2023 Non-covered Recipient Entity
CHEMIDOX CLINICAL TRIALS INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988708783
Principal investigator 1 Bavarian Nordic A/S $371.00 08/10/2023 Non-covered Recipient Entity
CHEMIDOX CLINICAL TRIALS INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988708789
Principal investigator 1 Bavarian Nordic A/S $1,168.00 07/18/2023 Non-covered Recipient Entity
CHEMIDOX CLINICAL TRIALS INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988708741
Principal investigator 1 Bavarian Nordic A/S $292.00 07/11/2023 Non-covered Recipient Entity
CHEMIDOX CLINICAL TRIALS INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988708777
Principal investigator 1 PFIZER INC. $865.35 07/06/2023 Non-covered Recipient Entity
Chemidox Clinical Trials Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045903963
Principal investigator 1 Bavarian Nordic A/S $292.00 07/04/2023 Non-covered Recipient Entity
CHEMIDOX CLINICAL TRIALS INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988708801
Principal investigator 1 Bavarian Nordic A/S $292.00 06/28/2023 Non-covered Recipient Entity
CHEMIDOX CLINICAL TRIALS INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988708697
Principal investigator 1 ModernaTX, Inc. $99.90 06/28/2023 Non-covered Recipient Entity
CHEMIDOX CLINICAL TRIALS - NEUROLOGY
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041660165
Principal investigator 1 Bavarian Nordic A/S $663.00 06/20/2023 Non-covered Recipient Entity
CHEMIDOX CLINICAL TRIALS INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988708727
Principal investigator 1 Bavarian Nordic A/S $292.00 06/13/2023 Non-covered Recipient Entity
CHEMIDOX CLINICAL TRIALS INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988708765
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796337
Principal investigator 1 ModernaTX, Inc. $5,209.87 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796345
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796353
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796361
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796371
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796381
Principal investigator 1 ModernaTX, Inc. $1,013.20 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796389
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796397
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796405
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796413
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796421
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796425
Principal investigator 1 ModernaTX, Inc. $1,013.20 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796433
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796441
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796451
Principal investigator 1 ModernaTX, Inc. $1,013.20 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796461
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796469
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796477
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796485
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796493
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796501
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796509
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796517
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796525
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796533
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796541
Principal investigator 1 ModernaTX, Inc. $5,209.87 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796549
Principal investigator 1 ModernaTX, Inc. $5,209.87 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796557
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796565
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796571
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796581
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796589
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796597
Principal investigator 1 ModernaTX, Inc. $1,013.20 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796605
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796613
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796621
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796629
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796640
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796649
Principal investigator 1 ModernaTX, Inc. $1,013.20 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796657
Principal investigator 1 ModernaTX, Inc. $1,013.20 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796665
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796673
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796681
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796691
Principal investigator 1 ModernaTX, Inc. $5,209.87 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796699
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796707
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796715
Principal investigator 1 ModernaTX, Inc. $5,209.87 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796723
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796731
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796739
Principal investigator 1 ModernaTX, Inc. $1,013.20 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796749
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041796757
Principal investigator 1 ModernaTX, Inc. $1,013.20 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797007
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797015
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797023
Principal investigator 1 ModernaTX, Inc. $5,209.87 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797031
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797039
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797047
Principal investigator 1 ModernaTX, Inc. $5,209.87 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797055
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797063
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797072
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797081
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797089
Principal investigator 1 ModernaTX, Inc. $5,209.87 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797095
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797103
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797113
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797121
Principal investigator 1 ModernaTX, Inc. $5,209.87 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797129
Principal investigator 1 ModernaTX, Inc. $5,209.87 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797137
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797145
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797153
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797161
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797169
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797177
Principal investigator 1 ModernaTX, Inc. $1,013.20 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797187
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797195
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797203
Principal investigator 1 ModernaTX, Inc. $5,209.87 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797211
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797219
Principal investigator 1 ModernaTX, Inc. $5,209.87 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797227
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797235
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797243
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797253
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797263
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797271
Principal investigator 1 ModernaTX, Inc. $5,209.87 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797279
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797287
Principal investigator 1 ModernaTX, Inc. $5,209.87 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797295
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797303
Principal investigator 1 ModernaTX, Inc. $1,013.20 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797313
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797321
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797329
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797337
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797345
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797353
Principal investigator 1 ModernaTX, Inc. $5,209.87 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797363
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797371
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797377
Principal investigator 1 ModernaTX, Inc. $5,209.87 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797389
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797397
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797407
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797415
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797423
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797433
Principal investigator 1 ModernaTX, Inc. $5,209.87 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797441
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797449
Principal investigator 1 ModernaTX, Inc. $5,209.87 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797459
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797467
Principal investigator 1 ModernaTX, Inc. $5,209.87 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797475
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797483
Principal investigator 1 ModernaTX, Inc. $5,209.87 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797491
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797499
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797507
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797515
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797523
Principal investigator 1 ModernaTX, Inc. $911.95 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797531
Principal investigator 1 ModernaTX, Inc. $911.95 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797541
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797549
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797557
Principal investigator 1 ModernaTX, Inc. $5,209.87 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797567
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797573
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797583
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797591
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797599
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797607
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797615
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797623
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797631
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797641
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797649
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797657
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797665
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797673
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797681
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797689
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797699
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797707
Principal investigator 1 ModernaTX, Inc. $1,013.20 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797715
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797723
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797731
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797739
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797747
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797755
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797763
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797771
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797779
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797787
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797795
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797803
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797811
Principal investigator 1 ModernaTX, Inc. $1,013.20 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797821
Principal investigator 1 ModernaTX, Inc. $5,209.87 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797829
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797837
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797845
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797853
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797863
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797871
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797879
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797887
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797895
Principal investigator 1 ModernaTX, Inc. $5,209.87 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797903
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797911
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797919
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797927
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797935
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797945
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797953
Principal investigator 1 ModernaTX, Inc. $5,209.87 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797961
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797969
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797977
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797985
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041797993
Principal investigator 1 ModernaTX, Inc. $1,013.20 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798001
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798009
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798017
Principal investigator 1 ModernaTX, Inc. $1,013.20 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798027
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798035
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798043
Principal investigator 1 ModernaTX, Inc. $1,013.20 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798051
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798059
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798067
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798075
Principal investigator 1 ModernaTX, Inc. $5,209.87 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798083
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041798091
Principal investigator 1 PFIZER INC. $52,786.35 06/08/2023 Non-covered Recipient Entity
Chemidox Clinical Trials Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045905681
Principal investigator 1 Bavarian Nordic A/S $371.00 05/30/2023 Non-covered Recipient Entity
CHEMIDOX CLINICAL TRIALS INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988708691
Principal investigator 1 PFIZER INC. $6,057.45 05/26/2023 Non-covered Recipient Entity
Chemidox Clinical Trials Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045906349
Principal investigator 1 PFIZER INC. $12,000.00 05/09/2023 Non-covered Recipient Entity
Chemidox Clinical Trials Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045906365
Principal investigator 1 Bavarian Nordic A/S $10,000.00 04/26/2023 Non-covered Recipient Entity
CHEMIDOX CLINICAL TRIALS INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988708667
Principal investigator 1 Bavarian Nordic A/S $2,500.00 04/26/2023 Non-covered Recipient Entity
CHEMIDOX CLINICAL TRIALS INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988708673
Principal investigator 1 Bavarian Nordic A/S $2,470.00 04/26/2023 Non-covered Recipient Entity
CHEMIDOX CLINICAL TRIALS INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988708685
Principal investigator 1 Bavarian Nordic A/S $2,439.00 04/26/2023 Non-covered Recipient Entity
CHEMIDOX CLINICAL TRIALS INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988708704
Principal investigator 1 Bavarian Nordic A/S $8,500.00 04/26/2023 Non-covered Recipient Entity
CHEMIDOX CLINICAL TRIALS INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988708825
Principal investigator 1 Bavarian Nordic A/S $292.00 04/18/2023 Non-covered Recipient Entity
CHEMIDOX CLINICAL TRIALS INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988708747
Principal investigator 1 Bavarian Nordic A/S $292.00 04/13/2023 Non-covered Recipient Entity
CHEMIDOX CLINICAL TRIALS INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988708771
Principal investigator 1 ModernaTX, Inc. $165.51 04/06/2023 Non-covered Recipient Entity
CHEMIDOX CLINICAL TRIALS - NEUROLOGY
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041659605
Principal investigator 1 Bavarian Nordic A/S $292.00 04/04/2023 Non-covered Recipient Entity
CHEMIDOX CLINICAL TRIALS INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988708807
Principal investigator 1 PFIZER INC. $11,700.00 03/24/2023 Non-covered Recipient Entity
Chemidox Clinical Trials Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045909892
Principal investigator 1 PFIZER INC. $22,890.00 03/23/2023 Non-covered Recipient Entity
Chemidox Clinical Trials Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045906379
Principal investigator 1 Bavarian Nordic A/S $1,460.00 03/21/2023 Non-covered Recipient Entity
CHEMIDOX CLINICAL TRIALS INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988708723
Principal investigator 1 Bavarian Nordic A/S $1,460.00 03/15/2023 Non-covered Recipient Entity
CHEMIDOX CLINICAL TRIALS INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988708759
Principal investigator 1 PFIZER INC. $14,415.00 03/08/2023 Non-covered Recipient Entity
Chemidox Clinical Trials Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045908613
Principal investigator 1 Bavarian Nordic A/S $876.00 02/22/2023 Non-covered Recipient Entity
CHEMIDOX CLINICAL TRIALS INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988708717
Principal investigator 1 Bavarian Nordic A/S $584.00 02/16/2023 Non-covered Recipient Entity
CHEMIDOX CLINICAL TRIALS INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988708753
Principal investigator 1 Bavarian Nordic A/S $292.00 02/02/2023 Non-covered Recipient Entity
CHEMIDOX CLINICAL TRIALS INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988708813
Principal investigator 1 Bavarian Nordic A/S $1,752.00 01/25/2023 Non-covered Recipient Entity
CHEMIDOX CLINICAL TRIALS INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988708711
Principal investigator 1 Bavarian Nordic A/S $876.00 01/20/2023 Non-covered Recipient Entity
CHEMIDOX CLINICAL TRIALS INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988708733
Principal investigator 1 Bavarian Nordic A/S $1,186.00 01/06/2023 Non-covered Recipient Entity
CHEMIDOX CLINICAL TRIALS INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988708795